Pays: Israël
Langue: anglais
Source: Ministry of Health
STREPTOKINASE
GENMEDIX , ISRAEL
B01AD01
POWDER FOR SOLUTION FOR INFUSION
STREPTOKINASE 750000 IU/VIAL
I.V, INTRA-ARTERIAL
Required
CSL BEHRING GmbH, GERMANY
STREPTOKINASE
STREPTOKINASE
Acute myocardial infarction, deep vein thrombosis, pulmonary embolism, acute or subacute thrombosis of peripheral arteries and chronic occlusive arterial diseases, occlusion of central retinal artery or vein.
2012-11-30
_STREPTASE 750 000:_ STREPTASE ® ACTIVE INGREDIENT: Stabilized pure streptokinase, derived from the culture filtrate of beta- haemolytic streptococci of Lancefield group C. It is presented as a white powder and contains stabilizers. QUALITATIVE AND QUANTITATIVE COMPOSITION _ACTIVE INGREDIENTS_ _STREPTASE 1 500 000:_ 1 injection vial with 147 to 192 mg dried substance contains 1 500 000 IU streptokinase. 1 injection vial with 139 to 182 mg dried substance contains 750 000 IU streptokinase. _OTHER INGREDIENTS_ Human albumin, Sodium-L-hydrogen glutamate monohydrate, Sodium dihydrogenphosphate dihydrate, Disodium hydrogenphosphate dihydrate. PHARMACEUTICAL FORM AND PRESENTATIONS _PHARMACEUTICAL FORM_ Powder for intravenous or intraarterial administration after reconstitution with physiological saline. _PRESENTATIONS_ Streptase 1 500 000 1 vial of 1 500 000 IU streptokinase Streptase 750 000 1 vial of 750 000 IU streptokinase PHARMACOTHERAPEUTIC GROUP Streptokinase (antithrombotic agents, enzymes). ATC-code: B01A D01 THERAPEUTIC INDICATIONS Streptase 750,000 IU: Acute myocardial infarction, deep vein thrombosis, pulmonary embolism, acute or subacute thrombosis of peripheral arteries and chronic occlusive arterial diseases, occlusion of central retinal artery or vein. Streptase 1,500,000 IU: Systemic administration: in deep vein thromboses, lung embolism, acute myocardial infarction for re- opening of coronary vessels. In acute and subacute thromboses of peripheral arteries and chronic occlusive arterial diseases, occlusion of central retinal artery or vein. Local administration: in acute myocardial infarction for re-opening of coronary vessels, in acute, subacute and chronic thromboses as well as embolisms of peripheral arteries. CONTRAINDICATIONS Streptase must not be used in case of severe allergic reactions to the product. Because of the increased risk of haemorrhage_ _under thrombolytic therapy, Streptase must not be given in the following situations: − existing or recent internal haemorrhages − all forms o Lire le document complet